)
Visual
earnings real time
Cipla
Cipla (CIPLA) investor relations material
Cipla Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary23 Jan, 2026
Executive summary
Q3 FY26 revenue was INR 7,074 crore, flat year-over-year, with India business up 10% YoY and strong chronic therapy growth, while U.S. revenues were impacted by lower Lenalidomide and lanreotide sales.
Strategic launches included Afrezza and Mounjaro in India, exclusive marketing/distribution deals with Pfizer, and acquisitions of Inzpera Healthsciences and Esperer Onco Nutrition.
North America saw Albuterol maintain #1 market share, but lanreotide supply was disrupted due to FDA observations; resupply expected in H1 FY27.
Unaudited financial results for Q3 FY26 were approved, with financial statements reviewed and receiving an unmodified review conclusion.
Exceptional item of INR 276 crore recognized due to increased employee benefit liabilities from new labour codes.
Financial highlights
EBITDA margin was 17.7% for Q3 FY26, down due to lower generic revenues and product mix; EBITDA at INR 1,255 crore.
Gross margin after material costs was 62.8%, affected by Lenalidomide decline and R&D/API purchases.
PAT was INR 676 crore (9.6% of sales), down 57% YoY, impacted by a one-time labour code expense.
R&D spend was INR 419–494 crore (7% of revenue), up 37.4% YoY, focused on filings and pipeline development.
Net cash position at INR 10,229 crore; total debt at INR 489 crore as of Dec 31, 2025.
Outlook and guidance
FY26 EBITDA margin guidance revised to around 21% due to lower-than-expected lanreotide and Lenalidomide performance.
U.S. revenue guidance for FY27 will be revised downward due to lanreotide disruption, but new launches are expected to support growth.
R&D spend expected to normalize to 5-6% of revenue, with some lumpiness based on project timing.
Acquisition of perpetual rights to manufacture and market Galvus brands for INR 1,107 crore, effective Jan 2026, to strengthen diabetes portfolio.
Explain confidence in favorable NPPA outcome
New Labour Codes: Any future financial impact
Galvus rights: Expected ROI or strategic value
Exclusivity and market size of key US launches
Strategy to defend margins post REVLIMID exit
Lanreotide supply disruption remediation plan
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- SVEA
Net profit rose 41% to 10,910 MSEK in 2025, with a proposed 1,338 MSEK dividend. - SWK
Gross margin and net income rose, with CAM divestiture set to reduce debt and boost 2026 outlook. - TOM2
Record Automotive backlog and margin gains offset a 3% revenue decline in 2025. - CMBT
Q1 profit, Golden Ocean merger, and decarbonization drive strong outlook. - CBT
Adjusted EPS down 13% to $1.53 as Battery Materials growth offset Reinforcement Materials decline. - ADVENZYMES
Q3 FY26 revenue up 2% YoY, PAT up 11%, with wind power SPV investment approved. - SIMO
Q4 2025 revenue and margins surged on SSD, eMMC/UFS, and automotive growth; 2026 outlook strong. - FSV
Annual revenue up 5% to $5.50B; Adjusted EBITDA and EPS both saw double-digit growth. - QLINEA
Over 400% revenue growth in 2025, with US expansion and breakeven targeted for 2027. - OMV
Clean CCS Operating Result down 10% year-over-year, with strong cash flow and 9.3% dividend yield.
Next Cipla earnings date
Q4 25/2612 May, 2026
Cipla
Next Cipla earnings date
Q4 25/2612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Cipla Limited is an India-based pharmaceutical company engaged in the development, manufacturing, and distribution of generic and branded medicines. The company’s product range spans respiratory, cardiovascular, anti-infective, and other therapeutic areas. Cipla Limited is headquartered in Mumbai, India, and its shares are listed on the NSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage